



Approved for use through 7/31/2006. OMB 0651-0031  
SUBSTITUTE for PTO/SB/08A (08-03). Information Disclosure Statement by Applicant  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449APTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Substitute for form 1449A/PTO 9 2004				COMPLETE IF KNOWN	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/730,704
				Filing Date	December 8, 2003
				First Named Inventor	R.P. Nargund et al.
				Group Art Unit	-- 1614
				Examiner Name	SPNACK
Sheet	1	of	5	Attorney Docket Number 21151	

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)	
PS		EP	0 920 864	PFIZER PRODUCTS INC.	06/09/1999
PS		WO	00/66578	PFIZER PRODUCTS INC.	11/09/2000
PS		WO	97/46250	SYNAPTIC PHARMACEUTICAL CORP.	12/11/1997
PS		WO	97/16189	MERCK & CO., Inc.	05/09/1997
PS		WO	96/40912	AMGEN Inc.	12/19/1996
PS		WO	97/06816	AMGEN Inc.	02/27/1997
PS		WO	97/18833	AMGEN Inc.	05/29/1997
PS		WO	98/28427	AMGEN Inc.	07/02/1998
PS		WO	02/060427	SEPRACOR Inc.	08/08/2002
PS		WO	02/060428	SEPRACOR Inc.	08/08/2002

**Examiner Signature** *P. Smith* **Date Considered** *9/17/06*

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder). Merck & Co., Inc., 09/05/2003

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet

2

of

5

Attorney Docket Number 21151

**COMPLETE IF KNOWN**

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE</b></p> <p><b>STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary)</i></p>				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/730,704
				Filing Date	December 8, 2003
				First Named Inventor	R.P. Nargund et al.
				Group Art Unit	--
				Examiner Name	
Sheet	2	of	5	Attorney Docket Number	21151

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
PS		WO 00/76493			NAJARIAN	12/21/2000
PS		WO 01/52825			NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.	07/26/2001
PS		WO 01/01969			ENDORECHERCHE, INC.	01/11/2001
PS		WO 02/32897			PFIZER PRODUCTS INC.	04/25/2002
PS		WO 98/18481			MERCK & CO., Inc.	05/07/1988
PS		WO 02/068388			MERCK & CO., Inc.	09/06/2002
PS		WO 02/019998			ELI LILLY AND COMPANY	03/14/2002
PS		WO 98/32441			SANOFI	07/30/1998
PS		WO 02/28346			AVENTIS PHARMA S.A.	04/11/2002

**Examiner  
Signature**

Phyllis Spivack

**Date Considered**

9/17/06

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO				<b>COMPLETE IF KNOWN</b>	
<b>INFORMATION DISCLOSURE</b>				Application Number	10/730,704
<b>STATEMENT BY APPLICANT</b>				Filing Date	December 8, 2003
(use as many sheets as necessary)				First Named Inventor	R.P. Nargund et al.
				Group Art Unit	--
				Examiner Name	
Sheet	3	of	5	Attorney Docket Number	21151

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
PS	AA	Farrigan et al., Nature Reviews - Drug Discovery, Vol. 1 (2002), "Obesity market overview", pp. 257-258.
PS	AB	Bray et al., Obesity Research, Vol. 7 (1999), "Sibutramine produces dose-related weight loss", pp. 189-198.
PS	AC	Kopelman, Nature, Vol. 404 (2000), "Obesity as a medical problem", pp. 635-643.
PS	AD	Steinbeck, Internal Medicine Journal (2002), Vol. 32, "Obesity: the science behind the management", pp. 237-241.
PS	AE	Qu et al., Nature, Vol. 380 (1996), "A role for melanin-concentrating hormone in the central regulation of feeding behaviour", pp. 243-247.
PS	AF	Davidson et al., JAMA, Vol. 281 (1999), "Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat", pp. 235-242.
PS	AG	Douglas et al., Int'l J. of Obesity, Vol. 7 (1983), "Plasma phentermine levels, weight loss and side-effects", pp. 591-595.
PS	AH	Guy-Grand et al., The Lancet (1989), "Therapeutics: International trial of long-term dexfenfluramine in obesity", pp. 1142-1144.
PS	AI	Muccioli et al., Eur. J. of Pharmacol., Vol. 440 (2002), "Neuroendocrine and peripheral activities of ghrelin...", pp. 235-254.
PS	AJ	Chamorro et al., Int'l J. of Obesity, Vol. 26 (2002), "Appetite suppression based on selective inhibition of NPY receptors", pp. 281-298.
PS	AK	Balasubramaniam, The American J. of Surgery, Vol. 183 (2002), "Clinical potentials of neuropeptide Y family of hormones", pp. 430-434.
PS	AL	Guerciolini, Int'l J. of Obesity, Vol. 21 (1997), Suppl. 3, "Mode of action of orlistat", pp. S12-S23.
PS	AM	Sletten et al., Current Therap. Res., Vol. 9 (1967), "Weight reduction with chlorphentermine and phenmetrazine in obese psychiatric patients during chlorpromazine therapy", pp. 570-575.
PS	AN	Kolakowska et al., Int'l Clinical Psychopharmacol., Vol. 2 (1987), "An open clinical trial of fenfluramine in chronic schizophrenia: A pilot study", pp. 83-88.
PS	AO	Pierson et al., J. Med. Chem., Vol. 40 (1997), "Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents", pp. 4302-4307.

Examiner Signature

PS Nwack

Date Considered

9/17/06

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO				<b>COMPLETE IF KNOWN</b>	
<b>INFORMATION DISCLOSURE</b>				Application Number	10/730,704
<b>STATEMENT BY APPLICANT</b>				Filing Date	December 8, 2003
(use as many sheets as necessary)				First Named Inventor	R.P. Nargund et al.
				Group Art Unit	--
				Examiner Name	
Sheet	4	of	5	Attorney Docket Number	21151

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
PS	AP	Bray et al., Nature, Vol. 404 (2000), "Medicinal strategies in the treatment of obesity", pp. 672-677			
PS	AQ	Kushner et al., Current Opinion in Gastroenterology, Vol. 18 (2002), "Obesity pharmacology: past, present, and future, pp. 213-220			
PS	AR	MacNeil et al., Eur. J. of Pharmacol., Vol. 440 (2002), "The role of melanocortins in body weight regulation...", pp. 141-157.			
PS	AS	Kirkham et al., Psychopharmacology, Vol. 153 (2001), "Synergistic effects (sic) of opioid and cannabinoid antagonists", pp. 267-270			
PS	AT	Boozer et al., Metabolism, Vol. 50 (2001), "Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats", pp 889-893.			
PS	AU	Wadden et al., Obesity Research, Vol. 8 (2000), "Effects of sibutramine plus orlistat in obese women following 1 year of treatment ..., pp. 431-437			
PS	AV	Zhou et al., Society for Neuroscience Abstracts, Vol. 27 (2001), 31st annual meeting of the Society for Neuroscience, San Diego, CA, November 10-15, 2001, "Attenuation of withdrawal reaction by a selective melanocortin MC4 receptor antagonist ...", p. 599			
PS	AW	Myrick et al., The American J. on Addictions, Vol. 10 (2001), "New developments in the pharmacotherapy of alcohol dependence", pp. 3-15.			
PS	AX	Angehelescu et al., J. of Clin. Psychopharmacol., Vol. 22 (2000), "Add-on combination and maintenance treatment ..., pp. 521-524			
PS	AY	Matson et al., Am. J. Physiol. Regulatory Integrative Comp. Physiol., Vol. 278 (2000), "Cholecystokinin and leptin act synergistically to reduce body weight", pp. R882-R890			
PS	AZ	Le et al., Alcohol & Alcoholism, Vol. 31 (1996), "Use of serotonin (5-HT) and opiate-based drugs in the pharmacotherapy of alcohol dependence ...", pp. 27-32.			
PS	BA	Chiesi et al., TRENDS in Pharmacological Sciences, Vol. 22 (2001), "Pharmacotherapy of obesity: targets and perspectives", pp 247-254			
PS	BB	Atkinson et al., Obesity Research, Vol. 3 (1995), "Combined drug treatment of obesity", pp. 497S-500S			
PS	BC	Raffa et al., Am. J. Med., Vol. 101, Suppl. 1A (1996), "A novel approach to the pharmacology of analgesics", pp. 40S-46S			
PS	BD	Fernandez-Lopez et al., Drugs, Vol. 62 (2002), "Pharmacological approaches for the treatment of obesity", pp. 915-944			

Examiner Signature	<i>P. Spinack</i>	Date Considered	9/17/06
--------------------	-------------------	-----------------	---------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO				<b>COMPLETE IF KNOWN</b>	
<b>INFORMATION DISCLOSURE</b>				Application Number	10/730,704
<b>STATEMENT BY APPLICANT</b>				Filing Date	December 8, 2003
<i>(use as many sheets as necessary)</i>				First Named Inventor	R.P. Nargund et al.
				Group Art Unit	--
				Examiner Name	
Sheet	5	of	5	Attorney Docket Number	21151

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
PS	BE	Lu et al., Peptides, Vol. 21 (2000), "Leptin resistance in obesity is characterized by decreased sensitivity to proopiomelanocortin products", pp. 1479-1485 -			
PS	BF	Dunbar et al., Brain Research Bulletin, Vol. 50 (1999), "Leptin-induced increase in sympathetic nervous and cardiovascular tone is mediated by proopiomelanocortin (POMC) products", pp. 215-221 .			
PS	BG	Bickerdike et al., Eur. J. of Pharmacology, Vol. 271 (1994), "The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze", pp. 403-411 .			
PS	BH	Proietto et al., Exp. Opin. Invest. Drugs, Vol. 9 (2000), "Novel anti-obesity drugs", pp. 1317-1326,			
PS	BI	Parker et al., Eur. J. of Pharmacology, Vol. 440 (2002), "Neuropeptide Y receptors as targets for anti-obesity drug development ...", pp. 173-187,			
PS	BJ	Rowland et al., Psychopharmacology, Vol. 159 (2001), "Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dextroamphetamine ...", pp. 111-116 .			
PS	BK	Sabath Silva et al., Revista de Investigacion Clinica, Vol. 54 (2002), "Leptina", pp. 161-165 .			
PS	BL	Chaki et al., Exp. Opin. Ther. Patents, Vol. 11 (2001), "Recent advances in feeding suppressing agents...", pp. 1677-1692 .			
PS	BM	Pomonis et al., The J. of Neuroscience, Vol. 17 (1997), "Interaction of the hypothalamic paraventricular nucleus and central nucleus of the amygdala in naloxone blockade ...", pp. 5175-5182 .			
PS	BN	Lalonde et al., Physiol. & Behavior, Vol. 80 (2004), "Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice", pp. 415-420 .			
PS	BO	Turton et al., Nature, Vol. 379 (1996), "A role for glucagon-like peptide-1 in the central regulation of feeding", pp. 69-72 .			
PS	BP	Erickson et al., Nature, Vol. 381 (1996), "Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y", pp. 415-418 .			
PS	BQ	Lonnqvist et al., Nature Medicine, Vol. 1 (1995), "Overexpression of the obese (ob) gene in adipose tissue of human obese subjects", pp 950-953 .			
PS	BR	De Vos et al., J. of Biol. Chem., Vol. 270 (1995), "Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake", pp. 15958-15961 ,			

Examiner Signature	<i>P. Spivack</i>	Date Considered	<i>9/17/06</i>
--------------------	-------------------	-----------------	----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

<p>Substitute for Form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE</b></p> <p><b>STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary)</i></p>				<p align="center"><b>COMPLETE IF KNOWN</b></p>	
Application Number		10/730,704			
Filing Date		December 8, 2003			
First Named Inventor		Ravi P. Nargund et al.			
Group Art Unit		1614			
Examiner Name		P.G. Spivack			
Sheet	1	of	2	Attorney Docket Number	21151

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number		
PS			WO 02/20488	F. Hoffman-La Roche AG	03/14/2002
PS			WO 02/38551	F. Hoffman-La Roche AG	05/16/2002
PS			WO 02/22592	Schering Corporation	03/21/2002
PS			WO 02/49648	Schering Corporation	06/27/2002
PS			WO 03/007887	Merck & Co., Inc.	01/30/2003
			WO 2004/058741	Merck & Co., Inc.	07/15/2004

**Examiner  
Signature**

P. Spivack

**Date Considered**

9/13/06

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Computer generated form "IDS Form" ((IDS Folder). Merck & Co., Inc. -7/12/2003

<p>Substitute for Form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE</b></p> <p><b>STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary).</i></p>				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/730,704
				Filing Date	December 8, 2003
				First Named Inventor	Ravi P. Nargund et al.
				Group Art Unit	1614
				Examiner Name	P.G. Spivack
Sheet	2	of	2	Attorney Docket Number	21151

## **NON PATENT LITERATURE DOCUMENTS**

**P. SOWDAK**

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated from "IDS Form" (IDS Folder) Merck & Co., Inc., 7/12/2005